{ "biomarker_id": "AN6278-5", "biomarker_canonical_id": "AN6278", "condition": { "recommended_name": { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a subtype of Betacoronavirus pandemicum." }, "synonyms": [ { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "description": "" }, { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "2019-nCoV infection", "description": "" }, { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "COVID19", "description": "" }, { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "SARS-CoV-2 infection", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "COVID-19", "description": "A disease caused by infection with severe acute respiratory syndrome coronavirus 2." }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "2019 novel coronavirus infection", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "2019-nCoV infection", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "coronavirus disease 2019", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "severe acute respiratory syndrome coronavirus 2 infectious disease", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "2019 novel coronavirus", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "2019-nCoV", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "SARS-CoV-2", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "SARS-coronavirus 2", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "beta-CoV", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "beta-CoVs", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "betacoronavirus", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "severe acute respiratory syndrome coronavirus 2", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "-CoV", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "-CoVs", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "-coronavirus", "description": "" } ], "id": "DOID:0080600" }, "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity_id": "P05231-1", "assessed_entity_type": "protein", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "Hybridoma growth factor" } ] }, "specimen": [ { "name": "blood", "namespace": "UBERON", "id": "0000178", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood plasma", "namespace": "UBERON", "id": "0001969", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "26881-3" }, { "name": "blood serum", "namespace": "UBERON", "id": "0001977", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" }, { "id": "32479790", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32479790", "tags": [ "assessed_biomarker_entity", " assessed_biomarker_entity_id", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." }, { "evidence": "Elevated IL-6 is a showing of cytokine storm in patients undergoing CAR-T therapy, requiring early action." }, { "evidence": "Serum IL-6 levels are signs of progression to multiple organ dysfunction in severe SARS-CoV-2 cases." } ] }, { "id": "32369209", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32369209", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ] }, { "id": "32259560", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32259560", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "Serial measurement of circulating IL-6 levels may be important in identifying disease progression among COVID-19-infected patients." } ] }, { "id": "32428990", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32428990", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "The decrease of IL-6 was closely related to treatment effectiveness, while the increase of IL-6 indicated disease exacerbation. Collectively, the dynamic change of IL-6 level can be used as a marker for disease monitoring in patients with severe COVID-19." } ] }, { "id": "32677844", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32677844", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ] }, { "id": "32438331", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32438331", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "A deep network analysis has suggested clinical biomarkers predicting the higher risk of severe COVID-19 infection: Hypertension, elevated serum Alanine aminotransferase, high Interleukin-6, and low Lymphocytes count. In particular, patients with diabetes, but also those with prediabetic state, deserve special attention.;|Clinical biomarkers for chronic inflammation, in particular Interleukin-6, predict the severity of COVID-19." } ] }, { "id": "32475810", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32475810", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts.;|Since the proportionate rise of IL-6 is correlated with disease severity, this study can prove ground-breaking." } ] }, { "id": "32234467", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32234467", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients." } ] }, { "id": "32442528", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32442528", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "findings in this study include determining independent associations between biomarkers for inflammation (interleukin-6) and thrombosis (D-dimer) and mortality." } ] }, { "id": "32161940", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32161940", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines. T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased. lower levels of regulatory T cells." } ] }, { "id": "32425269", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32425269", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "The maximal level of IL-6, followed by CRP level, was highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP level to guide escalation of treatment in patients with COVID-19-related hyperinflammatory syndrome." } ] }, { "id": "32385523", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32385523", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "Up-regulated IL-6 levels may serve as a potential marker for predicting progression of COVID19 patients." } ] }, { "id": "32181911", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32181911", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "IL-6 and d-D were closely related to the occurrence of severe COVID-19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID-19 patients, which has important clinical value." } ] }, { "id": "32344321", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32344321", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "The serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19." } ] }, { "id": "32286245", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32286245", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ] }, { "id": "32430456", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32430456", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "The mean of glycemia during hospitalization was 10.65 0.84 mmol/L in the no insulin infusion group and 7.69 1.85 mmol/L in the insulin infusion group. At baseline, IL-6 and D-dimer levels were significantly higher in the hyperglycemic group than in the normoglycemic group (P < 0.001). Even though all patients were on standard treatment for COVID-19 infection, IL-6 and D-dimer levels persisted higher in patients with hyperglycemia during hospitalization." } ] }, { "id": "32511562", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32511562", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "COVID-19 is associated with high levels of IL-6, TNF-a, IL-1b, and CXCL8/IL-8. IL-6 was one of the most robust prognostic markers of survival. It remained independently associated with severity and predictive of outcome. Furthermore, elevated TNF-a, known to contribute to organ damage, was also a strong predictor of poor outcome." } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" }, { "role": "predictive" } ], "evidence_source": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" }, { "id": "32479790", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32479790", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." }, { "evidence": "Elevated IL-6 is a showing of cytokine storm in patients undergoing CAR-T therapy, requiring early action." }, { "evidence": "Serum IL-6 levels are signs of progression to multiple organ dysfunction in severe SARS-CoV-2 cases." } ] }, { "id": "32369209", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32369209", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ] }, { "id": "32259560", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32259560", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Serial measurement of circulating IL-6 levels may be important in identifying disease progression among COVID-19-infected patients." } ] }, { "id": "32428990", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32428990", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "The decrease of IL-6 was closely related to treatment effectiveness, while the increase of IL-6 indicated disease exacerbation. Collectively, the dynamic change of IL-6 level can be used as a marker for disease monitoring in patients with severe COVID-19." } ] }, { "id": "32677844", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32677844", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ] }, { "id": "32438331", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32438331", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "A deep network analysis has suggested clinical biomarkers predicting the higher risk of severe COVID-19 infection: Hypertension, elevated serum Alanine aminotransferase, high Interleukin-6, and low Lymphocytes count. In particular, patients with diabetes, but also those with prediabetic state, deserve special attention.;|Clinical biomarkers for chronic inflammation, in particular Interleukin-6, predict the severity of COVID-19." } ] }, { "id": "32475810", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32475810", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts.;|Since the proportionate rise of IL-6 is correlated with disease severity, this study can prove ground-breaking." } ] }, { "id": "32234467", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32234467", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients." } ] }, { "id": "32442528", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32442528", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "findings in this study include determining independent associations between biomarkers for inflammation (interleukin-6) and thrombosis (D-dimer) and mortality." } ] }, { "id": "32161940", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32161940", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines. T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased. lower levels of regulatory T cells." } ] }, { "id": "32425269", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32425269", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "The maximal level of IL-6, followed by CRP level, was highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP level to guide escalation of treatment in patients with COVID-19-related hyperinflammatory syndrome." } ] }, { "id": "32385523", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32385523", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Up-regulated IL-6 levels may serve as a potential marker for predicting progression of COVID19 patients." } ] }, { "id": "32181911", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32181911", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "IL-6 and d-D were closely related to the occurrence of severe COVID-19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID-19 patients, which has important clinical value." } ] }, { "id": "32344321", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32344321", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "The serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19." } ] }, { "id": "32286245", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32286245", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ] }, { "id": "32430456", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32430456", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "The mean of glycemia during hospitalization was 10.65 0.84 mmol/L in the no insulin infusion group and 7.69 1.85 mmol/L in the insulin infusion group. At baseline, IL-6 and D-dimer levels were significantly higher in the hyperglycemic group than in the normoglycemic group (P < 0.001). Even though all patients were on standard treatment for COVID-19 infection, IL-6 and D-dimer levels persisted higher in patients with hyperglycemia during hospitalization." } ] }, { "id": "32511562", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32511562", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "COVID-19 is associated with high levels of IL-6, TNF-a, IL-1b, and CXCL8/IL-8. IL-6 was one of the most robust prognostic markers of survival. It remained independently associated with severity and predictive of outcome. Furthermore, elevated TNF-a, known to contribute to organ damage, was also a strong predictor of poor outcome." } ] }, { "id": "32576222", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32576222", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Levels of VEGF-D, TNF-alpha, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1 beta, and IFN-gamma were significantly higher in the critical group than in the severe group (Table 1)." } ] }, { "id": "32503382", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32503382", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Erythrocyte sedimentation rate (ESR) (R=0.55, p < .01) was positively associated with CT severity scores. To sum up, we can conclude from the analysis of published studies that hematological (lymphocyte count, neutrophil count, and NLR), inflammatory (CRP, ESR, IL-6), and especially biochemical (D-dimer, Troponins, CK) parameters correlate with severe prognosis or exitus in COVID-19 patients and can therefore be used as predictive biomarkers." } ] }, { "id": "32505227", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32505227", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ] }, { "id": "33303843", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/33303843", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Elevated levels of pro-inflammatory cytokines were present in patients with severe COVID19. IL-6 and MCP-1 were inversely correlated with P/F with the largest AUC in ROC analyses and should be further explored as biomarkers to identify patients at risk for severe RF and as targets for improved treatment strategies." } ] }, { "id": "33349241", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/33349241", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Significant correlations were found about age, IL2R, IL-6, IL-8, IL-10, TNF\u03b1, CRP, ferroprotein, PCT, LC, NC, and EC. PCT (R = -0.650), CRP (R = -0.604), NC (R = -0.585), age (R = -0.564), LC (R = 0.56), IL-6 (R = -0.535), IL2R (R = -0.534) and ferroprotein (R = -0.508) were highly correlated." } ] }, { "id": "32503877", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32503877", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production." } ] } ], "crossref": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5", "categories": [ "Biomarkers" ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020", "reference": [ { "type": "PubMed", "id": "32479790", "url": "https://glygen.org/publication/PubMed/32479790" } ], "evidence": [ { "id": "AN6697-1", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020", "reference": [ { "type": "PubMed", "id": "32369209", "url": "https://glygen.org/publication/PubMed/32369209" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Interleukin-6 as a potential biomarker of COVID-19 progression.", "journal": "Medecine et maladies infectieuses", "authors": "Ulhaq ZS, Soraya GV", "date": "2020", "reference": [ { "type": "PubMed", "id": "32259560", "url": "https://glygen.org/publication/PubMed/32259560" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.", "journal": "EMBO molecular medicine", "authors": "Liu Tao, Zhang Jieying, Yang Yuhui, Ma Hong, Li Zhenyu, Zhang Jiaoyue, Cheng Ji, Zhang Xiaoyun, Zhao Yanxia, Xia Zihan, Zhang Liling, Wu Gang, Yi Jianhua", "date": "2020-07-07", "reference": [ { "type": "PubMed", "id": "32428990", "url": "https://glygen.org/publication/PubMed/32428990" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "The association between biomarkers and clinical outcomes in novel coronavirus\u00a0pneumonia in a US cohort.", "journal": "Biomarkers in medicine", "authors": "Ayanian Shant, Reyes Juan, Lynn Lei, Teufel Karolyn", "date": "2020-08", "reference": [ { "type": "PubMed", "id": "32677844", "url": "https://glygen.org/publication/PubMed/32677844" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Diabetes and metabolic syndrome as risk factors for COVID-19.", "journal": "Diabetes & metabolic syndrome", "authors": "Marhl M, Grubelnik V, Magdic M, Markovic R", "date": "2020", "reference": [ { "type": "PubMed", "id": "32438331", "url": "https://glygen.org/publication/PubMed/32438331" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020", "reference": [ { "type": "PubMed", "id": "32475810", "url": "https://glygen.org/publication/PubMed/32475810" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.", "journal": "International journal of antimicrobial agents", "authors": "Zhang C, Wu Z, Li JW, Zhao H, Wang GQ", "date": "2020", "reference": [ { "type": "PubMed", "id": "32234467", "url": "https://glygen.org/publication/PubMed/32234467" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.", "journal": "Lancet (London, England)", "authors": "Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O'Donnell MR", "date": "2020", "reference": [ { "type": "PubMed", "id": "32442528", "url": "https://glygen.org/publication/PubMed/32442528" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020", "reference": [ { "type": "PubMed", "id": "32161940", "url": "https://glygen.org/publication/PubMed/32161940" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.", "journal": "The Journal of allergy and clinical immunology", "authors": "Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, Klein M, Weinberger T", "date": "2020", "reference": [ { "type": "PubMed", "id": "32425269", "url": "https://glygen.org/publication/PubMed/32425269" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "IL-6 may be a good biomarker for earlier detection of COVID-19 progression.", "journal": "Intensive care medicine", "authors": "Wang C, Fei D, Li X, Zhao M, Yu K", "date": "2020", "reference": [ { "type": "PubMed", "id": "32385523", "url": "https://glygen.org/publication/PubMed/32385523" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.", "journal": "Journal of medical virology", "authors": "Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L", "date": "2020", "reference": [ { "type": "PubMed", "id": "32181911", "url": "https://glygen.org/publication/PubMed/32181911" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.", "journal": "Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology", "authors": "Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X", "date": "2020", "reference": [ { "type": "PubMed", "id": "32344321", "url": "https://glygen.org/publication/PubMed/32344321" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G", "date": "2020", "reference": [ { "type": "PubMed", "id": "32286245", "url": "https://glygen.org/publication/PubMed/32286245" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?", "journal": "Diabetes care", "authors": "Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R", "date": "2020", "reference": [ { "type": "PubMed", "id": "32430456", "url": "https://glygen.org/publication/PubMed/32430456" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "An inflammatory cytokine signature helps predict COVID-19 severity and death.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Del Valle DM, Kim-Schulze S, Hsin-Hui H, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz T, Madduri D, Stock A, Marron T, Xie H, Patel MK, van Oekelen O, Rahman A, Kovatch P, Aberg J, Schadt E, Jagannath S, Mazumdar M, Charney A, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S", "date": "2020", "reference": [ { "type": "PubMed", "id": "32511562", "url": "https://glygen.org/publication/PubMed/32511562" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "VEGF-D: a novel biomarker for detection of COVID-19 progression.", "journal": "Critical care (London, England)", "authors": "Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H", "date": "2020", "reference": [ { "type": "PubMed", "id": "32576222", "url": "https://glygen.org/publication/PubMed/32576222" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Biomarkers associated with COVID-19 disease progression.", "journal": "Critical reviews in clinical laboratory sciences", "authors": "Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T", "date": "2020", "reference": [ { "type": "PubMed", "id": "32503382", "url": "https://glygen.org/publication/PubMed/32503382" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Immunology of COVID-19: Current State of the Science.", "journal": "Immunity", "authors": "Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salome B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, Gumus ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM", "date": "2020", "reference": [ { "type": "PubMed", "id": "32505227", "url": "https://glygen.org/publication/PubMed/32505227" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19.", "journal": "Scientific reports", "authors": "J\u00f8ntvedt J\u00f8rgensen Marthe, Holter Jan Cato, Christensen Erik Egeland, Schjalm Camilla, Tonby Kristian, Pischke S\u00f8ren Erik, Jenum Synne, Skeie Linda G, Nur Sarah, Lind Andreas, Opsand Hanne, Enersen Tone Burvald, Gr\u00f8ndahl Ragnhild, Hermann Anne, Dudman Susanne, Muller Fredrik, Ueland Thor, Mollnes Tom Eirik, Aukrust P\u00e5l, Heggelund Lars, Holten Aleksander Rygh, Dyrhol-Riise Anne Ma", "date": "2020-12-10", "reference": [ { "type": "PubMed", "id": "33303843", "url": "https://glygen.org/publication/PubMed/33303843" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.", "journal": "BMC infectious diseases", "authors": "Gong Jing, Dong Hui, Xia Qing-Song, Huang Zhao-Yi, Wang Ding-Kun, Zhao Yan, Liu Wen-Hua, Tu Sheng-Hao, Zhang Ming-Min, Wang Qi, Lu Fu-Er", "date": "2020-12-21", "reference": [ { "type": "PubMed", "id": "33349241", "url": "https://glygen.org/publication/PubMed/33349241" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] }, { "title": "Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.", "journal": "Science immunology", "authors": "Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, Roshon M, Wrzesinski SH, Desai JV, Zarakas MA, Collen J, Rose K, Hamdy A, Izumi R, Wright GW, Chung KK, Baselga J, Staudt LM, Wilson WH", "date": "2020", "reference": [ { "type": "PubMed", "id": "32503877", "url": "https://glygen.org/publication/PubMed/32503877" } ], "evidence": [ { "id": "AN6278-5", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6278-5" } ] } ], "section_stats": [ { "table_id": "biomarker_component", "table_stats": [ { "field": "total", "count": 1 } ], "sort_fields": [ "biomarker", "assessed_biomarker_entity_id", "assessed_entity_type", "assessed_biomarker_entity.recommended_name" ] }, { "table_id": "citation", "table_stats": [ { "field": "total", "count": 23 } ], "sort_fields": [ "title", "journal", "authors", "date" ] } ] }